Date: 2017-05-08
Type of information: Clinical research agreement
Compound: REGN2810 in combination with Pexa-Vec (pexastimogene devacirepvec)
Company: Regeneron Pharmaceuticals (USA - NY) Sillajen (Republic of Korea)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: oncolytic virus/gene therapy/oncolytic immunotherapy/monoclonal antibody/immune checkpoint inhibitor. Pexa-Vec (pexastimogene devacirepvec) is an oncolytic immunotherapy that utilizes the vaccinia poxvirus strain as its backbone. This strain has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells; Pexa-Vec was engineered to enhance this by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. Pexa-Vec is also engineered to express the immunogenic GM-CSF protein. GM-CSF complements the cancer cell lysis of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and sustained anti-tumoral immune attack. Pexa-Vec is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. REGN2810 is a fully human anti-PD-1 monoclonal antibody. Regeneron, in collaboration with Sanofi, is developing REGN2810 both alone and in combination with other therapies for the treatment of various cancers.
Disease: renal cell carcinoma
Details:
Financial terms:
Latest news: